Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 19, 2021 06:00 ET | Source: Brooklyn Immunotherapeutics LLC

Brooklyn ImmunoTherapeutics Announces Filing of Registration Statement for Proposed Secondary Offering of Shares Issued in Previously Announced Novellus Acquisition

NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”) today announced that on November 18, 2021 it filed with the Securities and Exchange...
November 09, 2021 16:35 ET | Source: Brooklyn Immunotherapeutics LLC

Brooklyn ImmunoTherapeutics Announces Third Quarter 2021 Financial Results

NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and...
October 14, 2021 16:15 ET | Source: Brooklyn Immunotherapeutics LLC

Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq

NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
September 23, 2021 16:30 ET | Source: Brooklyn Immunotherapeutics LLC

Brooklyn ImmunoTherapeutics Reports Inducement Grants

NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
September 22, 2021 10:07 ET | Source: Brooklyn Immunotherapeutics LLC

Brooklyn ImmunoTherapeutics Appoints Roger Sidhu, M.D. as Chief Medical Officer

NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
September 21, 2021 08:30 ET | Source: Brooklyn Immunotherapeutics LLC

Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021

NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
September 13, 2021 08:00 ET | Source: Brooklyn Immunotherapeutics LLC

Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Monday, September 20, 2021, at 4:30 PM ET

BROOKLYN, N.Y., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and...
September 09, 2021 08:30 ET | Source: Brooklyn Immunotherapeutics LLC

Brooklyn ImmunoTherapeutics to Participate in Grand Opening of Cambridge-Based mRNA Cleanroom Facility Shared with Factor Bioscience

NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
August 20, 2021 16:15 ET | Source: Brooklyn Immunotherapeutics LLC

Brooklyn ImmunoTherapeutics Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum

BROOKLYN, N.Y., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and...
August 20, 2021 08:30 ET | Source: Brooklyn Immunotherapeutics LLC

Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from August 19, 2021

NEW YORK, Aug. 20, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right